18 Patents
- US125401792026Compositions and Methods for Treating Cancer with Anti-ror1 Immunotherapy
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
0 cites - US124656412025Chimeric Antigen Receptor Therapies for Treating Solid Tumors
LENTIGEN TECHNOLOGY, Inc.
0 cites - US123917402025Compositions and Methods for Treating Cancer with Anti-bcma Immunotherapy
LENTIGEN TECHNOLOGY, Inc.
0 cites - US123919582025Compositions and Methods for Treating Cancer with Anti-cd38 Immunotherapy
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services
0 cites - US123714902025Compositions and Methods for Treating Cancer with Anti-cd19/cd22 Immunotherapy
LENTIGEN TECHNOLOGY, Inc.
0 cites - 0 cites
- 0 cites
- US121228312024Compositions and Methods for Treating Cancer with Anti-cd19/cd22 Immunotherapy
LENTIGEN TECHNOLOGY, Inc.
0 cites - US120374032024Compositions and Methods for Treating Cancer with Anti-cd123 Immunotherapy
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services
0 cites - US120245542024Compositions and Methods for Treating HIV/AIDS with Immunotherapy
LENTIGEN TECHNOLOGY, Inc.
0 cites - US119694432024Compositions and Methods for Treating Cancer with Self-driving Chimeric Antigen Receptors
LENTIGEN TECHNOLOGY, Inc.
0 cites - US119705282024Compositions and Methods for Treating Cancer with Anti-mesothelin Immunotherapy
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services
0 cites - 0 cites
- US118780522024Compositions and Methods for Treating Cancer with Anti-cd22 Immunotherapy
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services
0 cites - 0 cites
- US117084082023Compositions and Methods for Treating Cancer with Anti-cd19 Immunotherapy
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services
0 cites - US116801032023Compositions and Methods for Treating Cancer with Anti-cd19/cd20 Immunotherapy
LENTIGEN TECHNOLOGY, Inc.
0 cites - US115901692023Compositions and Methods for Treating Cancer with Anti-cd123 Immunotherapy
LENTIGEN TECHNOLOGY, Inc.
0 cites